These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 21766308

  • 1. Development of a new permeability assay using low-efflux MDCKII cells.
    Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD.
    J Pharm Sci; 2011 Nov; 100(11):4974-85. PubMed ID: 21766308
    [Abstract] [Full Text] [Related]

  • 2. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
    Guo A, Marinaro W, Hu P, Sinko PJ.
    Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
    [Abstract] [Full Text] [Related]

  • 3. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
    Colclough N, Alluri RV, Tucker JW, Gozalpour E, Li D, Du H, Li W, Harlfinger S, O'Neill DJ, Sproat GG, Chen K, Yan Y, McGinnity DF.
    Drug Metab Dispos; 2024 Jan 09; 52(2):95-105. PubMed ID: 38071533
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R, Jadhav G, Vangala S.
    Curr Pharm Biotechnol; 2017 Jan 09; 18(14):1151-1158. PubMed ID: 29521222
    [Abstract] [Full Text] [Related]

  • 5. Establishment of optimized MDCK cell lines for reliable efflux transport studies.
    Gartzke D, Fricker G.
    J Pharm Sci; 2014 Apr 09; 103(4):1298-304. PubMed ID: 24532159
    [Abstract] [Full Text] [Related]

  • 6. Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination.
    Chen EC, Broccatelli F, Plise E, Chen B, Liu L, Cheong J, Zhang S, Jorski J, Gaffney K, Umemoto KK, Salphati L.
    Mol Pharm; 2018 Nov 05; 15(11):5103-5113. PubMed ID: 30222362
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer.
    Li R, Bi YA, Lai Y, Sugano K, Steyn SJ, Trapa PE, Di L.
    AAPS J; 2014 Jul 05; 16(4):802-9. PubMed ID: 24854896
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV, Sateesh K, Panchagnula R.
    Mol Pharm; 2005 Jul 05; 2(1):12-21. PubMed ID: 15804173
    [Abstract] [Full Text] [Related]

  • 14. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.
    J Pharmacol Exp Ther; 2002 Dec 05; 303(3):1029-37. PubMed ID: 12438524
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.